Screener
Pelthos Therapeutics PTHS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.6%— | 76.3%— | 68.7%— | —— | —— | |
| Operating margin | -157.7%— | -193.1%— | -300.4%— | —— | —— | |
| Net margin | -186.2%— | -257.9%— | -318.4%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.4×— | 0.3×— | 0.1×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 2.8×+2.6× | 2.1×+1.7× | 2×+1.4× | 0.1×-0.8× | 0.2×-1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×— | 0.1×— | 0×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $10.60+255% | $20.68+525% | —— | —— | -$6.85— | |
| Valuation | ||||||
| Market capitalization | $78.48M+2.3% | $95.69M— | $85.9M— | —— | —— | |
| Price / sales | 2.8×-7.5× | 5.7×— | 11.6×— | —— | —— | |
| Price / book | 2.2×+0.9× | 2.5×— | 1.5×— | —— | —— |
FAQ
- What are Pelthos Therapeutics's profit margins?
- Pelthos Therapeutics (PTHS) runs a 79.6% gross margin and a -157.7% operating margin, with a -186.2% net margin.
- Where do Pelthos Therapeutics's ratios come from?
- Every ratio is computed from Pelthos Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
